Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 24726032)

1.

A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study.

Smith JD, Baillie J, Baglin T, Griffiths GO, Casbard A, Cohen D, Fitzmaurice DA, Hood K, Rose P, Cohen AT, Johnson M, Maraveyas A, Bell J, Toone H, Nelson A, Noble SI.

Trials. 2014 Apr 12;15:122. doi: 10.1186/1745-6215-15-122.

2.

Multicenter Randomized Controlled Trial on Duration of Therapy for Thrombosis in Children and Young Adults (Kids-DOTT): Pilot/Feasibility Phase Findings.

Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators.

J Thromb Haemost. 2015 Jun 28. doi: 10.1111/jth.13038. [Epub ahead of print]

PMID:
26118944
3.

Rivaroxaban for Cancer-Associated Cardiac Thrombosis.

Di Nisio M, Carella C, Natoli C, Porreca E, De Tursi M.

Am J Med. 2015 Jun 10. pii: S0002-9343(15)00515-X. doi: 10.1016/j.amjmed.2015.05.031. [Epub ahead of print] No abstract available.

PMID:
26071831
4.

I will recommend a clinical trial-if I can.

Sikov WM.

Am Soc Clin Oncol Educ Book. 2015;35:44-6. doi: 10.14694/EdBook_AM.2015.35.44. No abstract available.

5.

Changes in clinical trial length.

Pregelj L, Verreynne ML, Hine D.

Nat Rev Drug Discov. 2015 May;14(5):307-8. doi: 10.1038/nrd4611. No abstract available.

PMID:
25924577
6.

Should anticoagulation therapy be withheld in patients with active cancer after 6 months of low-molecular weight heparin?

Urrego EG, Carmona-Bayonas A, González-Billalabeitia E, Ayala de la Peña F.

J Clin Oncol. 2015 May 20;33(15):1713. doi: 10.1200/JCO.2014.60.6384. Epub 2015 Apr 13. No abstract available.

PMID:
25870093
7.

Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study.

Noble S, Prout H, Nelson A.

Patient Prefer Adherence. 2015 Feb 24;9:337-45. doi: 10.2147/PPA.S79373. eCollection 2015.

8.

Thrombosis Prevention without Anticoagulation.

Schmaier AH.

Front Med (Lausanne). 2014 May 9;1:12. doi: 10.3389/fmed.2014.00012. eCollection 2014. No abstract available.

9.

Parenteral anticoagulation in ambulatory patients with cancer.

Akl EA, Kahale LA, Ballout RA, Barba M, Yosuico VE, van Doormaal FF, Middeldorp S, Bryant A, Schünemann H.

Cochrane Database Syst Rev. 2014 Dec 10;12:CD006652. doi: 10.1002/14651858.CD006652.pub4. Review.

PMID:
25491949
10.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
11.

Anticoagulation for people with cancer and central venous catheters.

Akl EA, Ramly EP, Kahale LA, Yosuico VE, Barba M, Sperati F, Cook D, Schünemann H.

Cochrane Database Syst Rev. 2014 Oct 15;10:CD006468. doi: 10.1002/14651858.CD006468.pub5. Review.

PMID:
25318061
12.

Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.

Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, Schünemann H.

Cochrane Database Syst Rev. 2014 Jul 8;7:CD006650. doi: 10.1002/14651858.CD006650.pub4. Review.

PMID:
25004410
13.

Getting added value from using qualitative research with randomized controlled trials: a qualitative interview study.

O'Cathain A, Goode J, Drabble SJ, Thomas KJ, Rudolph A, Hewison J.

Trials. 2014 Jun 9;15:215. doi: 10.1186/1745-6215-15-215.

14.

[Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].

Nowak-Göttl U, Langer F, Limperger V, Mesters R, Trappe RU.

Dtsch Med Wochenschr. 2014 Jun;139(24):1301-6. doi: 10.1055/s-0034-1370110. Epub 2014 Jun 3. Review. German.

PMID:
24892468
15.

Low-molecular-weight heparin for prevention of venous thromboembolism after varicose vein surgery in moderate-risk patients: a randomized, controlled trial.

San Norberto García EM, Merino B, Taylor JH, Vizcaíno I, Vaquero C.

Ann Vasc Surg. 2013 Oct;27(7):940-6. doi: 10.1016/j.avsg.2013.03.006.

PMID:
23993109
17.

Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.

[No authors listed]

Prescrire Int. 2013 Apr;22(137):99-101, 103-4. Review.

PMID:
23662321
18.

Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.

Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Vénat-Bouvet L, Labourey JL, Martin J, Slaouti P, Tubiana-Mathieu N.

Cancer Chemother Pharmacol. 2013 Jul;72(1):65-73. doi: 10.1007/s00280-013-2169-y. Epub 2013 May 1.

PMID:
23636449
19.

[Adherence to guidelines for the treatment of venous thromboembolism in cancer patients: a retrospective analysis of 145 cases].

Belhadj Chaidi R, Thollot C, Ferru A, Roblot P, Landron C.

J Mal Vasc. 2013 May;38(3):185-92. doi: 10.1016/j.jmv.2013.03.001. Epub 2013 Apr 22. French.

PMID:
23619202
20.

Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence.

Hull RD, Townshend G.

Thromb Haemost. 2013 Jul;110(1):14-22. doi: 10.1160/TH12-12-0931. Epub 2013 Apr 25. Review.

PMID:
23615656
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk